Sarcoma vaccine: Phase II started

MabVax began a double-blind, U.S. Phase II trial to compare its subcutaneous sarcoma vaccine with adjuvant compared to adjuvant alone in 126 patients. MabVax licensed the vaccine from Memorial Sloan-K...